Suppression of the invasive potential of Glioblastoma cells by mTOR inhibitors involves modulation of NFκB and PKC-α signaling

Mechanisms regulating glioma invasion

(2015) Ivy Paw et al.   CANCER LETTERS

Current mechanistic insights into the roles of matrix metalloproteinases in tumour invasion and metastasis

(2015) Gordon T Brown et al.   JOURNAL OF PATHOLOGY

Significance of filamin A in mTORC2 function in glioblastoma

(2015) Naphat Chantaravisoot et al.   Molecular Cancer

Endothelial Cell mTOR Complex-2 Regulates Sprouting Angiogenesis

(2015) Maikel A. Farhan et al.   PLoS One

The NFκB pathway: a therapeutic target in glioblastoma

(2015) Lorena Nogueira et al.   Oncotarget

A conceptually new treatment approach for relapsed glioblastoma: Coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care.

(2015) Richard E. Kast et al.   Oncotarget

mTOR-targeted therapy: Differential perturbation to mitochondrial membrane potential and permeability transition pore plays a role in therapeutic response

(2014) Jae Eun Kim et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Emerging treatment strategies for glioblastoma multiforme

(2014) S. K. Carlsson et al.   EMBO Molecular Medicine

Astragaloside IV inhibits migration and invasion in human lung cancer A549 cells via regulating PKC-α-ERK1/2-NF-κB pathway

(2014) Xudong Cheng et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Vandetanib plus sirolimus in adults with recurrent glioblastoma: results of a phase I and dose expansion cohort study

(2014) Milan G. Chheda et al.   JOURNAL OF NEURO-ONCOLOGY

Expression and Regulation of Prostate Apoptosis Response-4 (Par-4) in Human Glioma Stem Cells in Drug-Induced Apoptosis

(2014) Jayashree C. Jagtap et al.   PLoS One

PKC signaling in glioblastoma

(2013) Anália do Carmo et al.   CANCER BIOLOGY & THERAPY

mTOR kinase inhibitors as potential cancer therapeutic drugs

(2013) Shi-Yong Sun   CANCER LETTERS

The mTOR Kinase Inhibitors, CC214-1 and CC214-2, Preferentially Block the Growth of EGFRvIII-Activated Glioblastomas

(2013) B. Gini et al.   CLINICAL CANCER RESEARCH

Glioblastoma Resistance to Anti-VEGF Therapy: Has the Challenge Been MET?

(2013) J. H. McCarty   CLINICAL CANCER RESEARCH

The long pentraxin PTX3 as a correlate of cancer-related inflammation and prognosis of malignancy in gliomas

(2013) Marco Locatelli et al.   JOURNAL OF NEUROIMMUNOLOGY

Protein kinase C and cancer: what we know and what we do not

(2013) R Garg et al.   ONCOGENE

Emerging insights into the molecular and cellular basis of glioblastoma

(2012) G. P. Dunn et al.   GENES & DEVELOPMENT

The brain tumor microenvironment

(2011) Nikki A. Charles et al.   GLIA

Oncogenic EGFR Signaling Activates an mTORC2-NF- B Pathway That Promotes Chemotherapy Resistance

(2011) K. Tanaka et al.   Cancer Discovery

A phase II study of cell cycle inhibitor UCN-01 in patients with metastatic melanoma: a California Cancer Consortium trial

(2010) Tianhong Li et al.   INVESTIGATIONAL NEW DRUGS

12-O-tetradecanoylphorbol-13-acetate-induced invasion/migration of glioblastoma cells through activating PKCα/ERK/NF-κB-dependent MMP-9 expression

(2010) Cheng-Wei Lin et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeutics

(2010) Camilla Krakstad et al.   Molecular Cancer

Rictor regulates MMP-9 activity and invasion through Raf-1-MEK-ERK signaling pathway in glioma cells

(2010) Gowry Das et al.   MOLECULAR CARCINOGENESIS

An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1

(2009) Carson C. Thoreen et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation

(2009) G. Solinas et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Low expression of tissue inhibitor of metalloproteinases-1 (TIMP-1) in glioblastoma predicts longer patient survival

(2009) Charlotte Aaberg-Jessen et al.   JOURNAL OF NEURO-ONCOLOGY

Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma

(2009) David A. Reardon et al.   JOURNAL OF NEURO-ONCOLOGY

A survey of glioblastoma genomic amplifications and deletions

(2009) Shailaja K. Rao et al.   JOURNAL OF NEURO-ONCOLOGY

Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2

(2009) Morris E Feldman et al.   PLOS BIOLOGY

Rapamycin inhibits F-actin reorganization and phosphorylation of focal adhesion proteins

(2008) L Liu et al.   ONCOGENE